Evidence map›Paper›PMID 41161820›Full record

ArticleJournal for immunotherapy of cancer2025

Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?

Mario Law de Lemos, Jane de Lemos, Victoria Kletas, Robyn Latt, Jelena Mucovic

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mario Law de LemosProvincial Pharmacy, BC Cancer Agency, Vancouver, British Columbia, Canada mdelemos@bccancer.bc.ca.
Jane de LemosProvincial Pharmacy, BC Cancer Agency, Vancouver, British Columbia, Canada.
Victoria KletasProvincial Pharmacy, BC Cancer Agency, Vancouver, British Columbia, Canada.
Robyn LattProvincial Pharmacy, BC Cancer Agency, Vancouver, British Columbia, Canada.
Jelena MucovicProvincial Pharmacy, BC Cancer Agency, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies suggest that acetaminophen may be linked to poorer long-term outcomes in patients receiving immune checkpoint inhibitors. Since acetaminophen is a widely used and essential medication for many patients with cancer, it is important to carefully evaluate the clinical significance of these findings. Using the WHO Causality Assessment and the Drug Interaction Probability Score to evaluate the available evidence, however, it seems unlikely or doubtful that there is a clinically significant interaction between acetaminophen and immune checkpoint inhibitor. We recommend that acetaminophen should not be restricted when used with checkpoint inhibitors until more robust evidence is available.

Indexed as

AcetaminophenImmune Checkpoint InhibitorsNeoplasmsDrug InteractionsHumansAcetaminophenImmune Checkpoint InhibitorsImmune Checkpoint InhibitorImmunotherapyPharmacodynamics - PDT cellT regulatory cell - Treg

Identifiers

PMID41161820
PMCPMC12574408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.